Literature DB >> 8920913

Molecular cloning and expression of human Gal beta 1,3GalNAc alpha 2,3-sialytransferase (hST3Gal II).

Y J Kim1, K S Kim, S H Kim, C H Kim, J H Ko, I S Choe, S Tsuji, Y C Lee.   

Abstract

A cDNA of human Gal beta 1,3GalNAc alpha 2,3-sialytransferase (hST3Gal II) which has been known to exhibit much more acceptor substrate preference for glycolipid than for O-linked oligosaccharides of glycoproteins, was isolated from the human liver cDNA library by plaque hybridization using the cDNA of mouse ST3Gal II (mST3Gal II) cloned previously as a probe. Comparative analysis of this cDNA with mST3Gal II indicates 89 and 94% homologies in the nucleotide and amino acid levels, respectively, between the two sequences in the predicted coding region. Northern analysis indicated that the expression of hST3Gal II mRNA is tissue-specific, it being prominent in skeletal muscle and heart, while that in lung and kidney is very low. This enzyme expressed in COS cells showed a similar activity with that of mST3Gal II.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8920913     DOI: 10.1006/bbrc.1996.1660

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  A systematic analysis of acceptor specificity and reaction kinetics of five human α(2,3)sialyltransferases: Product inhibition studies illustrate reaction mechanism for ST3Gal-I.

Authors:  Rohitesh Gupta; Khushi L Matta; Sriram Neelamegham
Journal:  Biochem Biophys Res Commun       Date:  2015-12-13       Impact factor: 3.575

3.  Multiplex RT-PCR method for the analysis of the expression of human sialyltransferases: application to breast cancer cells.

Authors:  M A Recchi; A Harduin-Lepers; Y Boilly-Marer; A Verbert; P Delannoy
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

4.  Regulation of sialyl-Lewis x epitope expression by TNF-alpha and EGF in an airway carcinoma cell line.

Authors:  Yuji Ishibashi; Yoshio Inouye; Teruo Okano; Akiyoshi Taniguchi
Journal:  Glycoconj J       Date:  2005-02       Impact factor: 2.916

Review 5.  Human airway mucin glycosylation: a combinatory of carbohydrate determinants which vary in cystic fibrosis.

Authors:  G Lamblin; S Degroote; J M Perini; P Delmotte; A Scharfman; M Davril; J M Lo-Guidice; N Houdret; V Dumur; A Klein; P Rousse
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

6.  Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma.

Authors:  Yongfu Zhao; Yanping Li; Hongye Ma; Weijie Dong; Huimin Zhou; Xiaobo Song; Jianing Zhang; Li Jia
Journal:  Mol Cell Proteomics       Date:  2013-11-19       Impact factor: 5.911

7.  ST3GAL2 knock-down decreases tumoral character of colorectal cancer cells in vitro and in vivo.

Authors:  Marlène Deschuyter; David Yannick Leger; Anne Verboom; Alain Chaunavel; Abderrahman Maftah; Jean-Michel Petit
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

8.  ST3Gal-4 is the primary sialyltransferase regulating the synthesis of E-, P-, and L-selectin ligands on human myeloid leukocytes.

Authors:  Nandini Mondal; Alexander Buffone; Gino Stolfa; Aristotelis Antonopoulos; Joseph T Y Lau; Stuart M Haslam; Anne Dell; Sriram Neelamegham
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

9.  alpha2,3-sialyltransferase ST3Gal III modulates pancreatic cancer cell motility and adhesion in vitro and enhances its metastatic potential in vivo.

Authors:  Marta Pérez-Garay; Beatriz Arteta; Lluís Pagès; Rafael de Llorens; Carme de Bolòs; Fernando Vidal-Vanaclocha; Rosa Peracaula
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

10.  Identification of seven new alpha2,3-sialyltransferase III, ST3Gal III, transcripts from human foetal brain.

Authors:  Ammi Grahn; Giti Shah Barkhordar; Göran Larson
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.